BioCentury | Dec 1, 2020
Product Development

Moderna moves & Immunocore breaks through: a BioCentury podcast

...surveys. For more information, please contact Eric Pierce and Josh Berlin at conferences@biocentury.com. BC Staff tebentafusp (IMCgp100, ImmTAC-gp100) Moderna...
BioCentury | Nov 23, 2020
Product Development

Immunocore charts the path for bispecifics in solid tumors with Phase III readout

...boundaries for the primary endpoint, overall survival, in an interim analysis of the Phase III IMCgp100-202...
...different funding sources to advance the pipeline.The company plans to share additional data from the IMCgp100-202...
...antigen A4NY-ESO-1 (CTAG1B) – Cancer/testis antigen 1BPRAME – Preferentially expressed antigen in melanoma Lauren Martz tebentafusp (IMCgp100, ImmTAC-gp100) Immunocore...
BioCentury | Mar 2, 2020
Finance

Immunocore’s $130M series B gives new CEO Jallal capital to progress pipeline

...will fund Immunocore through a readout of pivotal Phase II data for lead asset tebentafusp (IMCgp100...
...Injection” ). Targets CD3 PRAME - Preferentially expressed antigen in melanoma Stephen Hansen, Associate Editor tebentafusp (IMCgp100, ImmTAC-gp100) Immunocore...
BioCentury | Jun 1, 2019
Product Development

ASCO 2019 abstracts show solid tumor race heating up among bispecifics and CAR Ts

...marry bispecifics with another modality. Immunocore Ltd., for example, will present three abstracts for tebentafusp (IMCgp100...
...mucin domain 3 VEGF - Vascular endothelial growth factor Allison Johnson, Staff Writer AMG 119 JNJ-61186372, JNJ-6372 KN046 tebentafusp (IMCgp100, ImmTAC-gp100) Alligator...
BioCentury | Dec 15, 2018
Product Development

Extending Immunocore’s runway

...Genentech Inc. unit gives it enough cash to read out pivotal data from lead program IMCgp100...
...years' runway. The Genentech cash allows Immunocore to stretch its runway beyond 2020, when IMCgp100 (ImmTAC-gp100...
...And we believe in our approach, we have some proof of concept in IMCgp100.” If IMCgp100...
BioCentury | Jun 1, 2018
Clinical News

Immunocore reports Phase I/II data for uveal melanoma candidate

...melanoma in the Phase I portion of the Phase I/II IMCgp100-102 trial showing that IMCgp100 (ImmTAC-gp100...
...IMCgp100. Enrollment in the Phase II portion is slated to be completed in September 2019. IMCgp100...
...fused to an anti-CD3 antibody single-chain variable fragment (scFv). Immunocore Ltd., Abingdon, U.K. Product: IMCgp100, ImmTAC-gp100...
BioCentury | Sep 22, 2017
Finance

Immunocore’s Gates injection

...platform for infectious diseases after it had produced clinical data for its lead cancer program, IMCgp100...
BioCentury | Sep 22, 2017
Company News

Immunocore adds $40M from Gates Foundation

...tuberculosis and HIV. Most of Immunocore's pipeline is focused on cancer, with the lead program, IMCgp100...
...Ltd. , Abingdon, U.K. Bill & Melinda Gates Foundation , Seattle, Wash. Business: Infectious Elizabeth S. Eaton IMCgp100 Bill...
BioCentury | Sep 18, 2017
Financial News

Immunocore adds $40M from Gates Foundation

...tuberculosis and HIV. Most of Immunocore's pipeline is focused on cancer, with the lead program, IMCgp100...
BioCentury | Jun 16, 2017
Clinical News

Immunocore reports Phase I data for IMCgp100 in melanoma

...with metastatic uveal melanoma in an intra-patient dose-escalation Phase I trial showing that once-weekly IMCgp100 (ImmTAC-gp100...
...start a pivotal Phase II trial of IMCgp100 as first-line treatment of advanced uveal melanoma. IMCgp100...
...an anti-CD3 antibody single-chain variable fragment (scFv). Immunocore Ltd. , Abingdon, U.K. Product: IMCgp100 , ImmTAC-gp100...
Items per page:
1 - 10 of 31